1621470-75-4

Upstream product

• 22809-37-6 6-bromohexanoyl chloride 
• 1448960-09-5 C₂₆H₄₀F₃NO₆S 
• 1621470-73-2 (±)-(6-{2-[4-(2,4-dioxothiazolidin-(5Z)-ylidenemethyl)phenoxymethyl]-2,5,7,8-tetramethylchroman-6-yl}hexyl)carbamic acid tert-butyl ester 
• 74-88-4 methyl iodide 
• 4224-70-8 6-bromohexanoic acid 
• 1448960-05-1 (±)-6-(6-bromohexanoyl)-2,5,7,8-tetramethylchroman-2-carboxylic acid ethyl ester 
• 1448960-06-2 (±)-[6-(6-bromohexyl)-2,5,7,8-tetramethylchroman-2-yl]methanol 
• 1448960-07-3 (±)-[6-(6-azidohexyl)-2,5,7,8-tetramethylchroman-2-yl]methanol 
• 1448960-08-4 (±)-[6-(2-hydroxymethyl-2,5,7,8-tetramethylchroman-6-yl)hexyl]carbamic acid tert-butyl ester 
• 1448960-10-8 (±)-{6-[2-(4-formylphenoxymethyl)-2,5,7,8-tetramethylchroman-6-yl]hexyl}carbamic acid tert-butyl ester 

Downstream Products

• 1621471-42-8 (±)-(5Z)-{4-[6-(6-aminohexyl)-2,5,7,8-tetramethylchroman-2-ylmethoxy]benzylidene}-3-methylthiazolidine-2,4-dione trifluoroacetic acid salt 

Relevant academic research and scientific papers

Optimization of troglitazone derivatives as potent anti-proliferative agents: Towards more active and less toxic compounds

Δ2-Troglitazone derivatives were shown to exhibit anti-proliferative activity in a PPARγ-independent manner. We prepared various compounds in order to increase their potency and decrease their toxicity towards non-malignant primary cultured hepatocytes. Many compounds induced viabilities less than 20% at 10 μM on various cancer cell lines. Furthermore, five of them showed hepatocyte viability of 80% or more at 200 μM. In addition, compounds 17 and 18 exhibited promising maximum tolerated doses on a murine model, enabling future investigations.